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Introduction
More than three decades after the first cases of  Human 
Immunodeficiency Virus (HIV) infections were recognized, 
the epidemic in sub-Saharan Africa (SSA) has claimed the 
lives of  over 36 million people, and is still one of  the world’s 
most important public health issues1. However, in recent 
years, significant advances have been made to address the 
epidemic, in line with the political intent of  Millennium 
Development Goal 6, which was first to halve then begin to 
reverse the spread of  HIV by 20152. Key to this success has 
been the expansion of  antiretroviral therapy (ART), which 
has led to a 30-fold increase in ART coverage in SSA over 
the last decade3. 
For patients accessing ART, Acquired Immune Deficiency 
Syndrome (AIDS) has been transformed from a life-
limiting condition, with a median survival of  one year from 
diagnosis, into a chronic disease4, one which requires life-
long management5. However, the long-term retention of  
patients on ART has, itself, become a major challenge in 
SSA. In 2010, a systematic review of  39 papers found that 
30% of  patients were no longer taking their ARTs two years 
after starting treatment6. In the same review, it was noted 
that there was a paucity of  data as to why patients become 
lost to follow-up (LTFU) in SSA6. 
This study will examine the current prevalence and reasons 
for patients becoming LTFU in resource-poor settings. The 
particular focus is on Mulanje Mission Hospital (MMH) in 
Malawi, serving one of  the poorest regions of  a nation with 
the lowest Gross Domestic Product (GDP) per capita in the 
world7. 
Definitions 
Throughout the literature, there is no universal definition for 
patients who are not retained in ART programmes. The World 
Health Organization (WHO) defines retention as “patients 
known to be alive and receiving highly active ART (HAART) at the 
end of  a follow-up period.”8 This vague definition, which does 
not prescribe a specific follow-up period, has led to a wide 
disparity of  retention periods being used in the studies: 30 
days9, 3 months10, 6 months11 and 1 year12 are all quoted. 
Further confusion arises from the term ‘LTFU’ being 
used interchangeably with ‘attrition’ and ‘defaulting’ across 
studies5. In this report, LTFU has been utilized instead of  
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To analyse patients with HIV who were lost to follow-up from anti-retroviral therapy (ART) at Mulanje Mission Hospital (MMH), 
Malawi. 
Methods
All patients on adult antiretroviral combinations at MMH, who were classified as lost to follow-up (LTFU) according to the national 
guidelines (patients missing a scheduled follow-up visit by more than two months) over a 12-month period, were included in the study 
and compared against a control group who had never been lost. Variables compared were gender, age, months on ART, time of  year, 
WHO clinical stage, ART regimen, reported side effects, number of  doses missed in the previous 12 months, whether the patient has 
been followed up in the community and if  so, the length of  time elapsed before follow-up. 
Results
In all, 136 patients had been LTFU over the previous 12 months at MMH. Of  these, 43 had incomplete or missing ART cards, resulting 
in 93 LTFU patient’s data that could be analysed. Patients were more likely to get LTFU if  they were men (p=0.03), who had been on 
anti-retroviral therapy for a short duration (p=0.06) and the proportion of  patients who missed more than 4 doses in the previous 
12 months was higher among LTFU patients (p=0.05). Only 34.4% of  those LTFU had been traced in the community at the time of  
analysis. Of  those traced, 27% had moved to another area, 5.5% had died, 5.5% had the wrong documentation and 62% gave no reason 
as to why they had missed appointments. 
Conclusion
This study in MMH has highlighted the importance and feasibility of  comprehensive facility-level data-collection, both to identify local 
patient populations at risk of  becoming lost to follow-up and to assess the follow-up measures in place to bring these lost to follow-up 
patients back into the programme. Even in the short time and with the small sample that was collected, there was evidence that patients 
most likely to get LTFU in MMH were young men, who had been on anti-retroviral therapy for a short duration and had missed over 
4 doses in the last 12 months. 
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Patient demographics
There were a higher proportion of  male patients in the 
LTFU group (45.2%), when compared to the control group 
(30.1%) (p=.0.03). The mean age of  patients LTFU was 35.7 
years, 2.9 years younger than the control group on average 
(p=0.05).
WHO clinical stage at ART initiation
There was no statistically significant difference in the clinical 
stages, using the WHO clinical staging system, between the 
two groups (p=0.71).  
Time of year LTFU
The distribution of  the total patients (136) LTFU across the 
year was as follows: 26 in the 2nd quarter of  2015, 29 in the 
3rd quarter of  2015, 49 in the 4th quarter of  2015 and 32 in 
the 1st quarter of  2016. 
ART-regimen and length since initiation of ART
Of  the patients who were LTFU, 94.6% were taking ART 
regimen 5A (Tenofovir, Lamivudine and Efavirenz), the 
standard first line ART therapy in Malawi in 201524, and 2.2% 
and if  so, the length of  time elapsed before follow up. To 
highlight comparisons amongst the studied population (the 
LTFU group), a control group was identified and their data 
analysed. The control group was selected by using all of  the 
patients who attended the ART clinic between 18th and 22nd 
July 2016, and who had never defaulted. 
Statistical analysis
Comparison data for LTFU and controls were analysed using 
the chi squared (χ2) test, with alpha levels set at 0.05.
Ethical considerations
Ethical approval was sought and approved by the MMH 
medical director and hospital board. Confidentiality was 
maintained by coding the patient ART cards anonymously 
so that data was inputted and analysed separate from any 
patient identifiable information.
Results
In all, 136 patients had been LTFU over the previous 12 
months at MMH. Of  these, 43 patients had been missing 
ART cards, so the records of  93 patients LTFU were analysed. 
In the control group, 93 datasets were also analysed. 
the two latter terms, which have been criticized for assigning 
blame to the patients as opposed to a “non-judgmental term 
that simply describes an outcome”12. 
Prevalence of patients LTFU from ART in SSA 
The largest systematic review, which aimed to quantify the 
number of  patients retained on ART in SSA (using 39 cohort 
studies with a total of  226,307 patients), found that retention 
was 70% after 24 months6. Although this study brought 
substantial attention to the issue, it did not differentiate the 
three distinct cohorts of  patients who were not retained 
in care. One study which looked at samples of  patients 
not retained in ART across 13 countries in SSA, including 
Malawi, found these results: 56% were LTFU, 40% had died 
and 4% were retained in care despite stopping ART3. In 
2008, a more detailed single-cohort study in South Africa 
found that 31% of  their non-retained patients had died, 25% 
had transferred to another facility and 44% were LTFU13. 
Despite differences in the absolute proportions across the 
different studies, the recurring finding is that patients LTFU 
make up the biggest share of  patients not retained in ART 
programmes14,15. 
Reasons for patients LTFU in SSA 
Adherence to drug programmes is affected by the complex 
interplay of  self-care, community factors, care delivery and 
the drug itself15. Despite a paucity of  qualitative research 
in developing countries, many reasons have been identified 
or hypothesized for the significant proportion of  patients 
LTFU in ART programmes15. Several papers have identified 
financial constraints as a major cause of  LTFU in SSA16. 
One study in Malawi found that 24% of  patients originally 
recorded as LTFU, re-enrolled at the same site after ARTs 
were offered free of  charge16. However, the variation in 
adherence rates in different areas of  the country, irrespective 
of  free access, suggests that other barriers to treatment are 
involved17.  A qualitative study in Malawi’s southern region of  
Chiradzulu found that fear and stigma were the main reasons 
for LTFU18. Of  the 221 patients interviewed, 74% of  ART 
patients had not disclosed their HIV status to household 
members18. In addition, the only published systematic review 
examining the concerns of  HIV patients enrolled on ART 
programmes also found that fear of  disclosure was the most 
consistently cited barrier to treatment19. As well as discussing 
structural and socio-cultural issues, some research has 
concentrated on identifying which patient groups are most 
likely to become LTFU. Younger age at treatment initiation20, 
lower CD4 count at presentation6, type of  ART regimen21 
and the occurrence of  side effects15 have all been found to 
be associated with LTFU in the early stages of  treatment. 
Later on, a risk of  LTFU arises from patients experiencing 
an improvement in health and subsequently assuming that 
treatment is no longer necessary; 28.3% of  patients LTFU in 
rural Malawi cited improved health as their primary reason 
for leaving the programme18. 
HIV and ART in Malawi 
Malawi’s HIV prevalence is one of  the highest in the world, 
with the most recent Malawi Population-Based HIV Impact 
Assessment report estimating that 10.6% of  the population 
(over 1 million people) are living with HIV22. The epidemic 
has affected all sectors of  society, disproportionately 
targeting the youngest and most productive age groups, and 
has played a significant role in the country’s life expectancy 
of  only 54.8 years23. This burden is compounded by a 
shortage of  health workers; the ratio of  1 physician per 
50,000 people in Malawi is well below the WHO threshold 
of  twenty19.  Nevertheless, substantial efforts to reduce the 
burden of  HIV in Malawi have been made over the last 
decade, bringing about significant reductions in mortality, 
morbidity and transmission. New infections have declined 
from 98,000 in 2005 to 34,000 in 2013, gaining 1.4 million 
life-years as well as a 67% reduction in mother-to-child 
transmission over the same period8. This has largely been 
attributed to remarkable increases in ART coverage across 
the country, with over 500,000 individuals initiated on ART 
since the introduction of  free universal provision in 200419. 
Prior to this, ART was only available at a cost of  US$25 for 
a month’s supply17. However, ART adherence is variable. In 
2012, only 79% of  adults and children who started on ART 
in Malawi were taking them 12 months later, suggesting a 
significant proportion of  patients LTFU7. National Reports 
in 2009, 2010 and 2012 have shown rates of  LTFU of  12%, 
15% and 21% respectively, which indicate that the problem is 
increasing8,19 and with it, the impact on individuals. Patients 
missing visits in the first year of  treatment have a two-fold 
increase in long-term mortality24. There is also a health risk 
to the general public posed by the likely increase in drug 
resistance25. In response to this, in 2014, Malawi launched 
the 2015-2020 National HIV/AIDS Strategic Plan26. A key 
objective involves “maintaining high levels of  adherence and 
retention in ART programs”23. This study is a contribution to 
this objective; as the number and demographics of  patients 
LTFU from ART at MMH was not known, it provides this 
missing information and gives insight into the frequency and 
reasons patients may be LTFU locally. 
Methods
Study design
This was a retrospective notes-based review.
Setting
MMH is a mission hospital located in southern Malawi, 
close to the border with Mozambique. The hospital serves 
a catchment of  650,000 people who mainly live in rural 
villages and are reliant on farming for subsistence7. The 
largest part of  the hospital’s workload is in the assessment 
and treatment of  HIV/AIDS, with 10,714 HIV tests done 
and 74,136 ART clinic attendances during 2015 alone7. The 
most recent prevalence study in the area found that 18% of  
the population was living with HIV, significantly more than 
the national prevalence of  10.3%7. 
Data collection
Using an existing clinical dataset, all patients on adult 
antiretroviral formulations at MMH, who were classified as 
‘defaulters’ over the previous 12 months (2nd quarter 2015 – 
end of  1st quarter 2016), were included in the study. According 
to the local 2014 Malawian ART guidelines, defaulting was 
defined as “patients missing a scheduled follow- up visit by 
more than two months”22; a time frame that has recently 
been shown by Rachlis et al to represent the period (>9 
weeks) after which returning to clinic reduces substantially27. 
Data was collected from the patient cards stored in the 
outpatient ART clinic. The following variables were included 
in the analysis: gender, age, months on ART, time of  year 
LTFU, WHO clinical stage, ART regimen, reported side 
effects, number of  doses missed in the previous 12 months, 
whether the patient has been followed up in the community 
Table 1: Comparison data for LTFU and comparison groups
Lost to Follow Up 
(n= 93)
Controls (n=93)
Gender Male 42 (55%) 28 (30%)
Female 51 (45%) 65 (70%)
Age (years)             ≤20 3 (3.2%) 5 ( 5.4%)
21-30 22 (23.7%) 13 (14.0%)
31-40 36 (38.7%) 36 (38.7%)
41-50 22 (23.7%) 23 (24.7%)






1 39 (41.9%) 47 (50.5%)
2 18 (19.4%) 15 (16.1%)
3 30 (32.3%) 26 (28.0%)






0-12 18 (19.4%) 10 (10.8%)
13-24 20 (21.5%) 17 (18.3%)
25-36 9 (9.7%) 11 (11.8%)
37-48 18 (19.4%) 14 (15.1%)





in last 12 
months
0-3 48 (52%) 61 (66%)
≥4 45 (48%) 32 (34%)
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had documented side effects in the previous 12 months (1 
peripheral neuropathy and 1 hepatitis). The mean length of  
time on ART was 39.0 months in the LTFU group and 47.3 
months in the control group, with a mean difference of  8.3 
less months in the LTFU group (p=0.06). 
The mean number of  doses of  ART missed in the previous 
12 months was 13.15 in the LTFU group and 4.74 among 
controls, giving a mean difference of  8.41. When comparing 
the two groups, they were divided into those who had missed 
0-3 doses and those who had missed 4 or more doses, 
following the criterion used by the clinic for non-compliance. 
It was found that the proportion of  patients missing more 
than 4 doses was higher among the LTFU group compared 
to the controls (p=0.05).
Tracing
Of  the LTFU patients 34.4% had been traced in the 
community at the time of  analysis, with a mean length of  
time between clinic non-attendance and tracing of  13 weeks. 
According to the expert clients tracing the patients in the 
community, 27% had moved to another area, 5.5% had died, 
5.5% had the wrong documentation (incorrect addresses 
documented in client files) and 62% gave no reason as to 
why they had missed appointments. 
Discussion
The demographics of  the MMH dataset echo previous 
findings in Malawi, in which male patients are more likely 
to get LTFU on ART27. The proportion 
of  men in the LTFU group was 15.1% 
higher than in the control group, which 
was the only statistically significant finding 
of  the study, with a chi-squared p-value 
of  0.03. The reasons for this cannot be 
definitely ascertained, since no interviews 
were undertaken with men who had been 
LTFU. However, previous studies in Malawi 
have shown that men are also less likely to 
know about their HIV status and to access 
treatment than women, suggesting that the 
gender disparity is one that encompasses all 
areas of  HIV care17. The LTFU group also 
tended to be younger than the control group, 
with a mean difference of  3 years and a chi-
squared value of  0.06. Fear of  disclosure and 
stigma may be disproportionately affecting 
younger men, but more qualitative research 
is required to explore this. What this study, as 
well as a 2017 retrospective cohort study by 
Tweya et al, does illuminate is that both men 
and younger patients are at risk of  LTFU 
in Malawi28. Therefore, a recommendation 
is that interventions should be aimed 
specifically at men to improve their health 
outcomes. 
Time of year LTFU
A higher proportion of  those found LTFU 
were in the 4th quarter of  2015 and 1st 
quarter of  2016. These coincide with the 
rainy season in Mulanje District, which 
hinders the ability of  patients to travel over 
long distances. Although data over several 
years would be needed to confirm this trend, this is another 
matter warranting further research. Statistical confirmation 
could then be used to argue for more decentralised 
distribution of  ART during the rainy season. This has been 
further evidenced by a recent retrospective cohort study in 
Neno District which found that ART decentralisation halved 
the average distance to health centres and was associated 
with a 70% increase in retention in care29.
ART-regimen and length since initiation of ART
Two of  the most instructive findings from the study came 
from an examination of  the relationship between the length 
of  time on ART and the likelihood of  being LTFU. The 
mean length of  time on medication was 8.3 months less in 
the LTFU group, with a p-value of  0.05, emphasizing the 
need for more intensive follow-up in the early stages of  
treatment, when patients are at the highest risk of  LTFU. 
Patients were also more likely to get LTFU if  they had missed 
4 or more doses in the previous 12 months (p-value=0.05); 
so this represents another at-risk population who can be 
identified and could be given support before they get LTFU. 
The presence of  side effects was not predictive of  whether 
patients would get LTFU, with only 2.2% reporting them in 
the last 12 months. This is significantly lower than the figures 
quoted in trials looking at the rates of  side effects in the 
5A ART regimen, which is closer to 10%26. This is possibly 
related to a failure in MMH documentation and so needs 
further research, especially in the light of  a recent multi-
country qualitative study which found that every additional 
self-reported side effect increased the odds of  incomplete 
ART adherence by 10%30.
Tracing
Despite operating an expert client system in the clinic, 
attempting to trace and retrieve patients who miss their 
medication refills or appointments before they are officially 
classified as “defaulters”, only a third of  those LTFU had 
received follow-up visits at the time of  this study, suggesting 
that the community tracing is inconsistent. For those who 
were seen, the mean length of  time between clinic non-
attendance and tracing was 13 weeks. After taking into account 
the two-month delay that defines ‘defaulting’ in Malawi, this 
would mean a period of  more than five months without 
medication for these patients, putting them at significant risk 
of  adverse health consequences. When discussing this, one 
of  the expert clients reported that a main barrier to seeing 
patients quickly was a lack of  transport in the more remote 
areas, with their only bike currently broken and in need 
of  servicing. Early follow-up has been shown to improve 
retention, with the largest ART provider in central Malawi 
finding that following up patients within 3 weeks of  a missed 
appointment improved retention by 52%31. As only 45% of  
patients followed-up returned to clinic, this approach could 
be effective in MMH, but the expert clients will need to have 
access to better transport to try and achieve these results. 
Another potential improvement to be made in the follow-
up process is to take advantage of  the growing number of  
mobile phone users in the developing world, with a project 
in Kenya finding that phone contacting improved ART 
adherence rates32. The expert clients also said that using 
phones would make for a more efficient follow-up. However, 
they were not currently provided with phone credit; so again 
this would need more funding to be made available. 
Limitations
A significant limitation of  this study was a reliance on the 
routine notes provided by the clinic, which often had large 
gaps and contained inconsistencies. The 43 initial missing 
records represent a potential selection bias if  there are 
systematic differences between these patients and those 
analysed. Even when patient ART cards were available, some 
of  the data was not entered: 8 ages were not recorded and 
for many patients, only their year of  birth (not date) was 
documented. Absence of  accurate data could have been a 
source of  bias in age-related analyses. 
Furthermore, there was no follow-up of  two thirds of  the 
LTFU patients; so their outcomes represented an unknown 
quantity. Without knowing if  these patients had died, had 
moved elsewhere or had actively decided to stop treatment, 
very little can be inferred about their outcome. Of  the 
patients who were followed up, 62 % were documented as 
having “no reason” for leaving the programme. As their 
reasons are clearly more complex than that, these patients 
need to be interviewed in more depth to see whether they 
can be returned to the ART programme, with a view to 
reducing both morbidity and mortality. Ultimately, the 
biggest limitation was the study design; a case-control study 
design would be ideal. The way the control group was 
selected, which was by selecting patients attending over the 
course of  a week, may not be truly comparable to the LTFU 
group, which was selected over the course of  a year. This 
method was chosen as it was least disruptive to the running 
of  the clinic in the short time available for data collection. 
However, as the control group was was not randomly 
selected over the same time period as the LTFU group, the 
data was susceptible to significant selection bias.
Conclusion 
The global response to the challenge of  scaling up access 
to ART in the developing world signifies one of  the largest 
public health successes in recent history6. However, high 
rates of  LTFU have the potential to reverse the gains that 
have been achieved thus far. Therefore, a focus of  public 
health campaigns needs to be on long-term retention of  
patients on ART33. The failure of  patients to comply with 
their treatment should not be accepted as inevitable, but as a 
health injustice, affecting the poorest and most marginalized 
sectors of  HIV patients and invariably worsening their 
health outcomes. This study at Mulanje Mission Hospital, 
Malawi, has highlighted the importance of  comprehensive 
facility-level data-collection, both to identify local patient 
populations at risk of  becoming LTFU and to assess the 
follow-up measures in place to bring these LFTU patients 
back into the programme. The authors found evidence that 
patients most likely to get LTFU in MMH were young men, 
who had been on ART for a short duration and had missed 
over 4 doses in the last 12 months. The increase in patients 
LTFU during the 1st and 4th quarters of  the year needs 
further investigations and may highlight a need to provide 
larger quantities of  ART or to further decentralize the clinic 
during these times. There was also evidence of  serious 
inadequacies in the follow-up process, some of  which could 
be remedied by modest expenditure on bikes and phone 
credits. In the immediate future, there is an urgent need to 
understand why patients are LTFU in MMH, to develop 
targeted interventions to prevent it. In order to further 
understanding, it is proposed that a qualitative study using 
semi-structured interviews with LTFU patients should be 
planned and undertaken in the area. 
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